Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,630.00
-1,010.00 (-11.69%)
At close: Mar 4, 2026

Kwang Dong Pharmaceutical Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
316,739218,039297,799244,840305,229421,076
Market Cap Growth
46.34%-26.78%21.63%-19.79%-27.51%59.98%
Enterprise Value
430,106335,136283,794196,173300,829390,078
Last Close Price
8640.005340.007293.425771.707077.309633.43
PE Ratio
11.685.398.0610.1312.719.28
Forward PE
-14.3214.3214.3214.3214.32
PS Ratio
0.190.130.200.170.230.34
PB Ratio
0.500.350.510.450.580.84
P/TBV Ratio
0.570.400.590.490.630.91
P/FCF Ratio
46.15--6.549.8023.97
P/OCF Ratio
5.51--3.905.5618.45
EV/Sales Ratio
0.260.200.190.140.230.31
EV/EBITDA Ratio
11.237.515.163.755.105.88
EV/EBIT Ratio
20.4211.146.755.136.708.37
EV/FCF Ratio
62.67--5.249.6622.21
Debt / Equity Ratio
0.460.460.400.250.250.22
Debt / EBITDA Ratio
6.766.414.292.642.241.65
Debt / FCF Ratio
41.98--3.694.246.25
Net Debt / Equity Ratio
0.120.200.05-0.13-0.11-0.08
Net Debt / EBITDA Ratio
1.732.700.54-1.35-0.94-0.60
Net Debt / FCF Ratio
10.74-1.37-0.63-1.89-1.79-2.25
Asset Turnover
1.361.461.511.581.561.53
Inventory Turnover
6.596.626.957.346.586.21
Quick Ratio
1.020.951.031.231.321.24
Current Ratio
1.411.551.461.711.811.93
Return on Equity (ROE)
4.87%6.94%6.94%4.97%4.96%9.60%
Return on Assets (ROA)
1.32%1.67%2.62%2.63%3.28%3.59%
Return on Invested Capital (ROIC)
2.68%3.24%6.18%5.94%7.16%7.42%
Return on Capital Employed (ROCE)
3.50%4.20%6.80%6.60%8.00%8.80%
Earnings Yield
9.21%18.57%12.41%9.87%7.87%10.78%
FCF Yield
2.17%-40.31%-15.62%15.29%10.20%4.17%
Dividend Yield
1.27%--1.73%1.41%1.04%
Payout Ratio
13.46%9.90%11.11%16.99%17.10%6.98%
Buyback Yield / Dilution
1.64%1.10%1.48%0.11%-1.48%-2.24%
Total Shareholder Return
2.91%1.10%1.48%1.85%-0.07%-1.21%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.